Stories

 

Read success stories about NRC research, and how our work contributes to the success of our clients and partners.

 

""

- Boucherville, Quebec

Research Centre: Energy, Mining and Environment
Industry: Advanced Materials, Eco-friendly Energy, Energy and natural resources

- Ottawa, Ontario

Research Centre: Advanced Electronics and Photonics, Digital Technologies, Herzberg Astronomy and Astrophysics, Human Health Therapeutics
Industry: Pharmaceutical Manufacturing, Communication Technologies, Biopharmaceuticals, Astronomy

- Ottawa, Ontario

Research Centre: Advanced Electronics and Photonics, Herzberg Astronomy and Astrophysics
Industry: Electronic Systems and Components, Astronomy
""

- Ottawa, Ontario

Research Centre: Herzberg Astronomy and Astrophysics
Industry: Astronomy
""

- Ottawa, Ontario

Research Centre: Aerospace, Aquatic and Crop Resource Development, Herzberg Astronomy and Astrophysics, Industrial Research Assistance Program, Medical Devices
Industry: Space sciences
""

- Ottawa, Ontario

Research Centre: Human Health Therapeutics
""

- Edmonton, Alberta

Research Centre: Nanotechnology

- Ottawa, Ontario

Research Centre: Energy, Mining and Environment
Industry: Energy and natural resources
""

- Ottawa, Ontario

Research Centre: Human Health Therapeutics
""

- Ottawa, Ontario

Research Centre: Human Health Therapeutics
searchers:
•demonstrated that ZV can cross the blood-brain barrier
•showed that ZV infects glioblastoma cells to varying degrees, suggesting that genetically modified ZV could be developed to target therapeutics to glioblastoma cells
•developed a robust mouse model of ZV infection to test potential Zika vaccines
The NRC further leveraged its business relationship with Variation Biotechnologies Inc. (VBI) to bring the company's proprietary vaccine platform into this global effort to fight the emerging Zika epidemic. To this end, VBI and the NRC submitted a joint ZV grant proposal to the National Institute of Health. This strategic collaboration between VBI and the NRC has already led to the development of a plaque reduction neutralization assay at the NRC, and a collaborative research agreement to evaluate VBI's candidate enveloped virus-like particle (eVLP) vaccines is underway.